M&A / Deals Insilico Medicine, Takeda partner on AI-driven drug discovery Pharmaceutical Business ReviewUnder the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaceutical Business Review Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Read full story Post navigation Previous: FDA Selects Seven for PreCheck Pilot to Advance Drug ManufacturingNext: Roche’s KRAS drug tops its rivals in lung cancer trial Related Stories M&A / Deals Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset pharminent August 12, 2026 M&A / Deals Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront pharminent August 11, 2026 M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026
